ACRS - Aclaris Therapeutics rises 13% on insider buy
2023-08-29 11:51:18 ET
More on Aclaris Therapeutics
- Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch
- Aclaris stock falls ~35% as zunsemetinib fails mid-stage study in skin disorder
- Goldman Sachs initiates Aclaris at Buy citing potential in lead asset
- Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
- Seeking Alpha’s Quant Rating on Aclaris Therapeutics
For further details see:
Aclaris Therapeutics rises 13% on insider buy